US 12,409,218 B2
Influenza vaccine
Giuseppe Ciaramella, Cambridge, MA (US)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Filed by ModernaTX, Inc., Cambridge, MA (US)
Filed on Jan. 15, 2025, as Appl. No. 19/022,712.
Application 17/127,949 is a division of application No. 16/348,943, granted, now 10,925,958, issued on Feb. 23, 2021, previously published as PCT/US2017/061182, filed on Nov. 10, 2017.
Application 19/022,712 is a continuation of application No. 18/322,831, filed on May 24, 2023.
Application 18/322,831 is a continuation of application No. 17/127,949, filed on Dec. 18, 2020, granted, now 11,696,946, issued on Jul. 11, 2023.
Claims priority of provisional application 62/421,160, filed on Nov. 11, 2016.
Prior Publication US 2025/0235525 A1, Jul. 24, 2025
Int. Cl. A61K 39/145 (2006.01); A61K 9/51 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61P 31/16 (2006.01)
CPC A61K 39/145 (2013.01) [A61K 9/5123 (2013.01); A61P 31/16 (2018.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C12N 2760/16134 (2013.01)] 19 Claims
 
1. A vaccine comprising a messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame encoding an influenza virus hemagglutinin antigen formulated in a lipid nanoparticle (LNP), wherein 100% of uracil nucleosides in the open reading frame are N1-methylpseudouridine, wherein one dose of the vaccine contains 10-100 μg of the mRNA polynucleotide, wherein the LNP comprises 20-60 mol % cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid, wherein the cationic lipid comprises a cationic lipid of Formula (I):

OG Complex Work Unit Chemistry
or a salt or isomer thereof, wherein:
R1 is —R″M′R′;
R2 and R3 are each independently C1-14 alkyl,
R4 is —(CH2)nQ where Q is —OR, R is H, and n is 4;
R5, R6, and R7 are each H;
M and M′ are each —OC(O)—;
R′ is C1-18 alkyl;
R″ is C3-14 alkyl; and
m is 6.